FEATURED FUNDS
Axis Focused 25 Direct Plan-Growth
5Y Return
16.56 %
Invest Now
FEATURED FUNDS
Axis Long Term Equity Direct Plan-Growth
5Y Return
13.92 %
Invest Now
FEATURED FUNDS
SBI Small Cap Fund Direct-Growth
5Y Return
16.2 %
Invest Now
FEATURED FUNDS
Axis Bluechip Fund Direct Plan-Growth
5Y Return
14.86 %
Invest Now
FEATURED FUNDS
Mirae Asset Emerging Bluechip Fund Direct-Growth
5Y Return
17.08 %
Invest Now
TUNE IN NOW FOR NEWS & VIEWS
The Morning Brief (ET Bureau)
Vaccine Reality Dose
Indulekha Aravind | 17:59 Min | November 24, 2020, 2:18 PM IST
Bharat Biotech failed to halt clinical trials after one person developed serious side-effects during the testing of Covaxin, its indigenously developed Covid-19 vaccine candidate. Dr. Srinath Reddy, President of Public Health Foundation of India, and ET’s Teena Thacker take us through the protocols and challenges of developing a vaccine.
Transcript
Host: Indulekha Aravind
